Document is current
Any future updates will be listed below
-
Authors
Zullig, Leah L. https://orcid.org/0000-0002-6638-409X
Shahsahebi, Mohammad
Neely, Benjamin
Hyslop, Terry
Avecilla, Renee A. V.
Griffin, Brittany M.
Clayton-Stiglbauer, Kacey
Coles, Theresa
Owen, Lynda
Reeve, Bryce B.
Shah, Kevin
Shelby, Rebecca A.
Sutton, Linda
Dinan, Michaela A.
Zafar, S. Yousuf
Shah, Nishant P.
Dent, Susan
Oeffinger, Kevin C.
-
Funding
Funding for this research was provided by:
national cancer institute (1R01CA249568-01, P30CA014236)
- License Information
-
More Information
Article History
Received: 29 September 2021
Accepted: 19 October 2021
First Online: 18 November 2021
Declarations
:
: This study was approved by the Duke Institutional Review Board. Study participants provided written informed consent.
: N/A: This is paper describes a protocol.
: The authors report no financial or non-financial interests related to the current work.Unrelated to the current work, Dr. Zullig reports research funding from Proteus Digital Health and the PhRMA Foundation, as well as consulting from Novartis and Pfizer. Dr. Zafar reports employment and stock from Shattuck Labs (to his spouse), serving on advisory boards for Vivor, LLC (uncompensated) and Cancer Support Community (uncompensated), serving on the Board of Directors ffor Family Reach (uncompensated), and being a board member for WCG IRB. Dr. Zafar also reports research funding from AstraZeneca and consulting for RTI, McKesson, Quintiles, and Change Healthcare. Dr. Dent reports research funding from Novartis.
